Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Robyn M. Dennis"'
Autor:
Tanya M. Trippett, Luciano Dalla-Pozza, Alan S. Wayne, Ira Pastan, Jessica Boklan, Yves Bertrand, John Moppett, Meina Liang, Francoise Mechinaud, Paul L. Martin, Susan R. Rheingold, Claudine Schmitt, Franco Locatelli, Robyn M. Dennis, André Baruchel, Inna Vainshtein, Nirali N. Shah, Keith J. August, Nobuko Hijiya, Deepa Bhojwani, Kemal Balic, Xia Li, Nai Shun Yao
Publikováno v:
Pediatr Blood Cancer
Background In a multicenter phase 1 study of children with relapsed/refractory acute lymphoblastic leukemia (ALL), moxetumomab pasudotox, an anti-CD22 immunotoxin, demonstrated a manageable safety profile and preliminary evidence of clinical activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::670d497307f26ca40f2a21fd1c087455
https://doi.org/10.1002/pbc.28112
https://doi.org/10.1002/pbc.28112
Autor:
Rebecca Gardner, Javier Oesterheld, Steven G. DuBois, Paul S. Gaynon, Kenneth Heym, Van Huynh, Sima Jeha, Maria Luisa Sulis, Cara A Rabik, Richard Sposto, Erin M. Guest, Michelle L. Hermiston, Alan S. Wayne, Akira Yuno, Julia Glade-Bender, David S. Ziegler, Shannon Kelley, Patrick A. Brown, Jessica A. Pollard, Bill H. Chang, Sunmin Lee, Rumen Kostadinov, Lia Gore, Anupam Verma, Theodore W. Laetsch, Joel A. Kaplan, Jane B. Trepel, Michael J. Burke, Midhat S. Farooqi, Byunggil Yoo, Robyn M. Dennis, Todd M. Cooper, Deepa Bhojwani, Min-Jung Lee
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 10
Clin Cancer Res
Clin Cancer Res
Purpose: Treatment failure from drug resistance is the primary reason for relapse in acute lymphoblastic leukemia (ALL). Improving outcomes by targeting mechanisms of drug resistance is a potential solution. Patients and Methods: We report results in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b4f13f594d65d6f8294813c53c5483
https://escholarship.org/uc/item/11p345nm
https://escholarship.org/uc/item/11p345nm
Autor:
Jennifer J. Wilkes, Henrique Bittencourt, Francesco Ceppi, Javier Oesterheld, Richard Sposto, Yoav Messinger, Susan R. Rheingold, Maria Luisa Sulis, David S. Ziegler, Rebecca Gardner, Weili Sun, Andrew E. Place, Robyn M. Dennis, Todd Cooper, Nobuko Hijiya, Anupam Verma, Yousif Matloub, Michelle L. Hermiston, Melissa Widener, Alan S. Wayne, Paul S. Gaynon, Kirk R. Schultz, Kenneth Heym, Van Huynh, Luciano Dalla-Pozza, Raymond J. Hutchinson, James A. Whitlock, Bill H. Chang, Jemily Malvar, Theodore W. Laetsch
Publikováno v:
Leukemia, vol. 32, no. 11, pp. 2316-2325
Leukemia, vol 32, iss 11
Leukemia
Leukemia, vol 32, iss 11
Leukemia
The survival of pediatric patients with multiply relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia has historically been very poor; however, data are limited in the current era. We conducted a retrospective study to determine the o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b7e63e383e4c283537e733bde29e451
https://doi.org/10.1038/s41375-018-0094-0
https://doi.org/10.1038/s41375-018-0094-0
Autor:
Kenneth Heym, Christiane Chen-Santel, Jennifer J. Wilkes, Franco Locatelli, James A. Whitlock, Gerhard Zugmaier, Arend von Stackelberg, Catherine A. Tuglus, Huakang Tu, Christina Peters, Richard Sposto, Aaron J. Katz, Robyn M. Dennis, Luciana Vinti, Nathalya Zubarovskaja, Michael A. Kelsh, Victoria M. Chia, Weili Sun, Anupam Verma
Publikováno v:
Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb834ee83e800229bc5b468e85b5f70
https://pubmed.ncbi.nlm.nih.gov/32094465
https://pubmed.ncbi.nlm.nih.gov/32094465
Autor:
Elena Eckroth, Jemily Malvar, Alan S. Wayne, Jeannette Vandergiesse, Paul S. Gaynon, Weili Sun, James A. Whitlock, Anupam Verma, Richard Sposto, Kenneth Heym, Robyn M. Dennis, Jennifer J. Wilkes
Publikováno v:
Blood. 126:3760-3760
Introduction Remission induction rates after a second or greater relapse is a critical endpoint in phase II trials of childhood acute lymphoblastic leukemia (ALL). A robust benchmark is crucial for identification of novel multi-agent regimens worthy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f66745ea276085201bed6ad6a46df5f6
https://doi.org/10.1182/blood.v126.23.3760.3760
https://doi.org/10.1182/blood.v126.23.3760.3760
Publikováno v:
Blood. 116:2904-2904
Abstract 2904 Survival has improved dramatically in acute lymphoblastic leukemia (ALL), but further gains are unlikely using conventional chemotherapy alone. Several recently discovered, novel cytogenetic lesions with adverse prognostic impact, JAK2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74e2c4cdd75133ae5ce80edf995ae47c
https://doi.org/10.1182/blood.v116.21.2904.2904
https://doi.org/10.1182/blood.v116.21.2904.2904